NCT00076934View on ClinicalTrials.gov

Safety of RG2077 in Patients With Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

February 28, 2006

Conditions
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

RG2077 (CTLA4-IgG4m)

RG2077

Trial Locations (1)

02115

Brigham and Women's Hospital/Harvard Medical School, Boston

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

collaborator

Repligen Corporation

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00076934 - Safety of RG2077 in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter